News coverage about TrovaGene (NASDAQ:TROV) has trended somewhat positive this week, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. TrovaGene earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 46.1810101694423 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Manage Your Risk Before Making Any Investment Decision – TrovaGene, Inc., (NASDAQ: TROV) – Stock Watch (stocksnewstimes.com)
- Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM … – PR Newswire (press release) (prnewswire.com)
- Trovagene Announces Activation of First Clinical Trial Site in Phase 1b/2 Acute Myeloid Leukemia (AML) Trial for PCM-075 (finance.yahoo.com)
- Trovagene Announces Third Quarter 2017 Company Highlights and Financial Results (finance.yahoo.com)
- Trovagene reports 3Q loss (finance.yahoo.com)
Shares of TrovaGene (NASDAQ:TROV) traded up $0.01 during trading hours on Tuesday, hitting $0.68. The company had a trading volume of 171,600 shares, compared to its average volume of 579,926. TrovaGene has a 52 week low of $0.61 and a 52 week high of $3.50.
TrovaGene (NASDAQ:TROV) last announced its quarterly earnings data on Thursday, November 9th. The medical research company reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.02. The company had revenue of $0.12 million during the quarter. TrovaGene had a negative return on equity of 259.94% and a negative net margin of 7,960.05%.
A number of research analysts recently issued reports on the company. Maxim Group downgraded TrovaGene from a “buy” rating to a “hold” rating in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of TrovaGene in a research note on Tuesday, August 8th.
COPYRIGHT VIOLATION WARNING: “TrovaGene (TROV) Earns Media Sentiment Score of 0.19” was first published by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.thestockobserver.com/2017/11/14/trovagene-trov-earns-media-sentiment-score-of-0-19.html.
TrovaGene Company Profile
Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.
Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with MarketBeat.com's FREE daily email newsletter.